NIPT CE IVD Growth Yourgene has launched CE IVD NIPT and expanded its NIPT workflow capabilities, including IONA Care Plus service offerings. This presents an opportunity to target European and UK laboratories seeking regulatory compliant, locally supported NIPT solutions and to upsell a complete end to end NIPT package backed by the Manchester based clinical service lab.

Oncology DPYD Opportunity DPYD pharmacogenomics The DPYD genotyping assay enables safer chemotherapy by detecting risk for fluoropyrimidine toxicity. Target oncology centers, hospital labs and pharmacogenomics service providers with a value proposition centered on precision dosing and treatment safety; propose bundled testing programs and integration with existing diagnostic workflows.

Automation Workflow ROI Automation and workflow optimization Ranger automated DNA size selection instruments and LightBench offer high throughput, compact lab automation for NIPT, gene synthesis, CRISPR and long read sequencing. Target mid to large genomic labs looking to consolidate instruments, reduce hands on time, and improve turnaround; provide ROI focused pilots and favorable install base.

Global Deployment Advantage Global reach and regional service With headquarters in Manchester and facilities in Singapore, the US and Canada, under the Novacyt group, Yourgene can support cross border installations, regional service, and local regulatory navigation. This enables pursuing international lab contracts and faster deployment of NIPT and precision medicine workflows.

Portfolio Cross Sell Portfolio driven cross sell Yourgene portfolio spans reproductive screening NIPT CF testing aneuploidy pregnancy loss male factor infertility thrombosis risk and precision medicine DPYD. This invites cross selling across fertility clinics, obstetrics and hospital genetics labs offering integrated testing menus and streamlined lab workflows from a single vendor.